International Symposium

ACUTE LEUKEMIAS XIII
Biology and Treatment Strategies

organized by the

German AML Cooperative Group (AMLCG)

together with the

Ludwig Maximilians-University Munich (LMU)

HelmholtzZentrum München
German Research Center for Environmental Health

SFB 684 Molecular Mechanisms or Normal and Malignant Hematopoiesis

German Society for Hematology and Oncology

Verein für Leukämieforschung und –Therapie e.V.

February 27 – March 2, 2011
Munich, Germany

Second Announcement

and Call for Abstracts
Organisation in Charge:

Verein für Leukämieforschung und -Therapie e.V. Münster

Cooperating Institutions:

LMU

Klinikum der Universität München
Medizinische Klinik und Poliklinik III

HelmholtzZentrum München
German Research Center for Environmental Health

Deutsche Gesellschaft für Hämatologie und Onkologie

German AML Cooperative Group

SFB 684

SFB 684 Molecular Mechanisms of Normal and Malignant Hematopoiesis
Dear Colleagues:

the 13th International Symposium on ACUTE LEUKEMIAS that is held in Munich, February 27 – March 2, 2011, provides again the opportunity to discuss the most recent findings in basic research and actuarial results of clinical studies with international experts in these fields. You are cordially invited to use this forum to become updated on recent developments in the complex field of leukemia research and therapy. You may also take the opportunity to present your own data in the context of the poster and the best of free contribution sessions.

The Special Lecture during the opening session will set the stage by Mel Greaves, one of the most renowned experts on the field of leukemia research. In addition, Satellite Symposia and Meet-the-Expert Sessions will deliver further chances to discuss advances and perspectives of basic science and treatment strategies.

The organizing committee and I am looking forward to an exciting Symposium on ACUTE LEUKEMIAS and I will be pleased to welcome you in Munich.

Yours

W. Hiddemann
ORGANIZING COMMITTEE:

Prof. Dr. W. Hiddemann, Munich
Prof. Dr. Th. Büchner, Münster
Prof. Dr. J. Braess, Munich
Priv.-Doz. Dr. K. Spiekermann, Munich
Priv.-Doz. Dr M. Subklewe, Munich
Dr. O. Christ, Munich

NATIONAL SCIENTIFIC COMMITTEE:

Prof. Dr. D. Beelen, Essen
Prof. Dr. A. Borkhardt, Düsseldorf
Prof. Dr. M. Bornhäuser, Dresden
Prof. Dr. U. Creutzig, Hannover
Prof. Dr. H. Döhner, Ulm
Prof. Dr. J. Duyster, Munich
Prof. Dr. D. Hoelzer, Frankfurt
Prof. Dr. W.K. Hofmann, Mannheim
Prof. Dr. J. Ritter, Münster
Prof. Dr. M. Schmitt, Rostock
Prof. Dr. M. Schrappe, Kiel
Prof. Dr. H. Serve, Frankfurt
Prof. Dr. B. Wörmann, Bremen

INTERNATIONAL SCIENTIFIC COMMITTEE

Prof. Dr. M. Andreeff, Houston, USA
Prof. Dr. C. Bloomfield, Columbus, USA
Prof. Dr. A.K. Burnett, Cardiff, UK
Prof. Dr. C. Eaves, Vancouver, Canada
Prof. Dr. E.H. Estey, Seattle, USA
Prof. Dr. W.E. Fibbe, Leiden, NL
Prof. Dr. D. J. Grimwade, London, UK
Prof. Dr. R.K. Humphries, Vancouver, Canada
Prof. Dr. G. Kvalheim, Oslo, Norway
Prof. Dr. R.A. Larson, Chicago, USA
Prof. Dr. B. Löwenberg, Rotterdam, NL
Prof. Dr. M.F. Martelli, Perugia, Italy
Prof. Dr. M. Manz, Zurich, CH
Prof. Dr. R. Ohno, Nagoya, Japan
Prof. Dr. P. Pandolfi, New York, USA
Prof. Dr. Ch.H. Pui, Memphis, USA
Prof. Dr. M. Sanz, Valencia, Spain
Prof. Dr. C.A. Schiffer, Detroit, USA
Prof. Dr. R. Stone, Boston, USA

POSTER AWARD COMMITTEE

Prof. Dr. E. Lengfelder, Mannheim, Germany
Prof. Dr. J. Rowe, Haifa, Israel

LEUKEMIA CLINICAL RESEARCH AWARD COMMITTEE

Prof. Dr. H. Döhner, Ulm, Germany
Prof. Dr. G. Dölkem, Greifswald, Germany
Prof. Dr. A. Ganser, Hannover, Germany
Prof. Dr. A. Hochhaus, Jena, Germany
Prof. Dr. J. Ritter, Münster, Germany
Prof. Dr. B. Wörmann, Bremen, Germany
MAIN TOPICS

Characterization of Leukemic Stem Cells

Molecular Mechanisms and Clinical Correlates in AML and ALL

Biology and Therapy of AML with t(15;17)

Risk adapted Therapy of Pediatric and Adult AML

Risk-Adapted Transplantation Strategies in AML and ALL

From Bench to Bedsite – Novel Experimental Concepts

Risk-Adapted Therapy of Pediatric and Adult ALL

Immunotherapy of Acute Leukemias

Management of Elderly and Frail patients

Relevance of MRD in AML and ALL
### SCIENTIFIC PROGRAM

#### at a glance

**Accompanying Symposia**

**Sunday, Feb 27, 2011**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Sponsor</th>
</tr>
</thead>
</table>
| 09.30-11.00| **Satellite Symposium I**
  (sponsored by Hoffmann-La Roche AG) |                                |
| 11.15-12.15| **Satellite-Symposium II**
  (sponsored by mundipharma GmbH) |                                |
| 13.00-14.45| **Satellite Symposium III**
  (sponsored by MEDA Pharma) |                                |
| 15.00-16.00| **Satellite Symposium IV**
  (sponsored by GILEAD Sciences GmbH) |                                |
| 16.30-18.30| **Interdisziplinäres Fortbildungsseminar**
  “Arbeitsgemeinschaft Infektionen” in der
  Hämatologie und Onkologie der DGHO |                                |

**Main Sessions**

**Monday, Feb 28, 2011**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.00-09.30</td>
<td><strong>Welcome Addresses</strong></td>
<td></td>
</tr>
<tr>
<td>09.30-10.15</td>
<td><strong>Special Lecture</strong></td>
<td></td>
</tr>
</tbody>
</table>
| 10.45-12.25| **MS I:**
  Characterization of Leukemic Stem Cells                  |                                                                         |
| 12.45-13.45| **Meet-the-Professor Sessions**                           |                                                                         |
| 14.00-15.40| **MS II:**
  Genetic and Molecular Characterization of Acute Leukemias |                                                                         |
| 16.10-18.00| **MS III:**
  Biology and Management of AML with t(15;17)               |                                                                         |
| 18.00-19.30| **MS IV:**
  Poster Viewing and Discussion                             |                                                                         |
<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Program</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.00-10.40</td>
<td>MS V: Risk adapted Therapy of AML</td>
</tr>
<tr>
<td>11.10-13.10</td>
<td>MS VI: Management of Elderly and Frail Patients with AML</td>
</tr>
<tr>
<td>13.30-14.00</td>
<td>Meet-the-Professor Sessions</td>
</tr>
<tr>
<td>14.15-15.55</td>
<td>MS VII: Relevance of Minimal Residual Disease in AML and ALL</td>
</tr>
<tr>
<td>16.25-18.05</td>
<td>MS VIII: Immunotherapy of Acute Leukemias</td>
</tr>
<tr>
<td>18.30-19.15</td>
<td>MS IX: Best of Free Contributions</td>
</tr>
</tbody>
</table>

**Wednesday, Mar 2, 2011**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Program</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.00-10.40</td>
<td>MS X: Risk adapted Therapy of ALL</td>
</tr>
<tr>
<td>11.10-12.50</td>
<td>MS XI: Allogeneic Transplantation</td>
</tr>
<tr>
<td>12.50-13.00</td>
<td>Closing Remarks</td>
</tr>
</tbody>
</table>
GENERAL INFORMATION

Scientific Program: Sunday, February 27 – Wednesday, Mar 2, 2011

Location: Ludwig-Maximilians-University (LMU)
           Klinikum Großhadern (Hörsaaltrakt)
           Marchioninistraße 15
           D-81377 Munich, Germany

Official Language: English

Oral Presentations: All Main Sessions are plenary and non-parallel.

Free Oral and Poster Presentation: Additional contributions will be presented in an oral session (Best of Free Contributions) and as posters. Poster Session will be held on Monday, Feb. 28, Best of Free Contributions Session will be held on Tuesday, Feb. 29, 2011.

How to register: All registrations must be done via electronically: www.acute-leukemias.de

Official Homepage: All necessary details about the registration modus, registration fees, and registration deadlines are listed below and at www.acute-leukemias.de

Organizing Office: Beate Buske-Kosel, M.A.
                   Am Webstuhl 5
                   D-59227 Ahlen, Germany
                   Phone: +49-(0)2382-7601 457 (new number valid after Nov 8, 2010)
                   Fax: +49-(0)2382-7601 458 (new number valid after Nov 8, 2010)
                   e-mail: info@acute-leukemias.de

Aleksandra Schydlik
Department of Internal Medicine III
University Hospital Großhadern
Ludwig-Maximilians-University
Marchioninistraße 15
D-81377 Munich, Germany
Phone: +49(0)897095-5530
Fax: +49-(0)897095-5550
| Registration Deadlines and Registration Fee: | “Early” registration fee: € 180  
Registration and Payment before December 1, 2010 |
|-------------------------------------------|--------------------------------------------------|
| “Advance” registration fee: € 200  
Registration and Payment: after December 1, 2010, but before February 15, 2010 |
| On-site registration fee: € 250  
Registration after February 15, 2010 or on-site |

**Method of Payment:**
Advance payment can be made by check, money order or can be credited to our account:
- **Account Holder:** Verein für Leukämieforschung e.V.
- **Bank:** Sparkasse Münsterland Ost
- **Bank Code:** 400 501 50
- **Account No:** 1900 2468
- **Key word:** ACUTE LEUKEMIAS XIII - 2011
- **IBAN:** DE 64400 501 5000 1900 2468
- **BIC-Code:** WELADED1MST

*All payments must carry your name and the key word ACUTE LEUKEMIAS XIII - 2011*

The registration includes admission to all scientific sessions, the reception on Sunday evening, February 27, 2011, and the Abstract Booklet

**Free access to all sessions !**
- Speakers, Chairmen, and Members of the Scientific Committees of ACUTE LEUKEMIAS XIII
- Members of the AMLCG Study Group
- Members of the Medical Faculty of Munich
- Students and Nurses (confirmation required)
- Invited representatives of the participating industrial partners (confirmation required)

**Earn CME through ACUTE LEUKEMIAS XIII**
Hematologists can earn continuing medical education credits through participation in ACUTE LEUKEMIAS XIII
Awards: Again, two Poster Awards of € 500 will be granted to young scientists who are presenters of abstracts in the poster sessions. The “Leukemia Clinical Research Award 2011” (LCRA) which is endowed with € 7,500, will be granted to a young investigator presenting a scientific paper in the field of clinical or preclinical research. Candidates must submit their application until the submission deadlines.

Best of Free Contributions and LCRA Presentations: The 5 best free contributions and the winner of the Leukemia Clinical Research Award will be invited to present their data in Main Session IX.


GUIDELINES FOR THE SUBMISSION OF ABSTRACTS

In order to be considered for poster presentation or best of free contribution session, abstracts must be submitted via e-mail on the official abstract form!

In order to submit your abstract as required, please refer to the symposium homepage: www.acute-leukemias.de Download the abstract form and send the electronic version of your abstract to: info@acute-leukemias.de

NOTE: With the electronic submission of an abstract the author/s transfer/s all copyright ownership to the organizers of the Symposium ACUTE LEUKEMIAS XIII.

All abstracts will be reviewed by the Scientific Committee. If accepted, presenters are expected to attend at least one full day of scientific sessions and to participate in the poster session, in which their poster/s is/are presented.
GUIDELINES FOR THE SUBMISSION OF ABSTRACTS

In order to be considered for the best of free contribution session or for poster presentation, abstracts must be submitted via e-mail on the official abstract form!

In order to submit your abstract please refer to the symposium homepage: www.acute-leukemias.de Download the abstract form and send the electronic version of your abstract to: info@acute-leukemias.de

NOTE: With the electronic submission of an abstract the author/s transfer/s all copyright ownership to the organizers of the Symposium ACUTE LEUKEMIAS XIII.

All abstracts will be reviewed by the Scientific Committee. If accepted, presenters are expected to attend at least one full day of scientific sessions and to participate in the oral or poster session, in which their contribution/s is/are presented.

Abstract submission deadline is November 30, 2010

GUIDELINES FOR THE PREPARATION OF ABSTRACTS

Contents:

1. The official language is English
2. The abstract should contain a short title, followed by authors and institutions
3. The purpose of the study should be stated, followed by methods, results and conclusion.

Instructions for typing:

1. Abstracts should be written in a Courier-font no smaller than 10-point and typed single spaced.
2. Simple tables or graphs – neat and in black ink – may be included if they fit within the rectangle of the form.
3. Capitalize title (e.g. TREATMENT OF RELAPSED AML OF CHILDHOOD WITH DAUNOXOME-FLAG ....)
4. Names of authors should not be capitalized: Initials must precede last name (e.g. G. Fleischhack)
5. Underline presenting author (e.g. N. Graf)
6. Mention institution, city, and country (e.g. Dept. of Pediatric Hematology, University of Bonn, Germany)
Social Events:  

SUNDAY, February 27, 2011, 20.00 – 23.30 h

Welcome Reception

at the
Hotel LeMERIDIEN
Bayerstraße 4
D-80335 Munich

Admission:
Free Access. All participants of the meeting, accompanying persons, and exhibitors are cordially invited to participate in the Welcome Reception which will be held in the banqueting hall of the Hotel.

Public Transport:
All lines which stop at Munich main station; from there it is a 5 minutes' walk from the south exit (see map on last page)

TUESDAY, March 1, 2011, 20.00 - 23.30 h

Social Evening and Informal Dinner

at
KÜNSTLERHAUS am Lenbachplatz
Am Lenbachplatz 8
D-80333 Munich
Phone: +49(0)89-59 91 84-0

Admission:
Free access: invited speakers, chairmen, and members of the scientific committees
€ 20,00: students, nurses, and members of the faculties of Munich and Muenster
€ 30,00: regular participants

Public Transport: U4/5 to Karlsplatz/Stachus; from there 5 minutes' walk across the street.

Advance Registration  www.acute-leukemias.de
Commercial Exhibition: A commercial exhibition will be displayed at the first floor of the meeting center:

**Opening hours are:**

- **Sunday,** Feb 27, 2011: 10.00a.m.-06.00p.m.
- **Monday,** Feb 28, 2011: 09.00a.m.-06.00p.m.
- **Tuesday,** Mar 01, 2011: 09.00a.m.-06.00p.m.
- **Wednesday,** Mar 02, 2011: 09.00a.m.-01.00p.m.

Why exhibit at AL XIII? Exhibiting at the **ACUTE LEUKEMIAS XIII** meeting renders the opportunity to meet clinicians and basic researchers from all branches of hematology from all over the world ensuring that your services and products will be accessible to a highly specialized audience.

Companies interested in exhibiting at **ACUTE LEUKEMIAS XIII** are asked to e-mail info@acute-leukemias.de for more information about how to apply for exhibit space.

Other Corporate Support Opportunities: Companies interested in receiving more details about all support opportunities as e.g. about the possibility to host a Satellite Symposium or a Meet-the Professor Session are asked to e-mail for further information info@acute-leukemias.de.
The support of the symposium ACUTE LEUKEMIAS XIII by the following companies is gratefully acknowledged (preliminary list):

**Gold Circle Corporate Member:**
MEDA Pharma GmbH & Co. KG (Satellite Symposium)

**Silver Circle Corporate Members:**
GILEAD Sciences GmbH (Satellite Symposium)
Hoffmann-La Roche AG (Satellite Symposium)
Mundipharma GmbH (Satellite Symposium)
Pfizer Pharma GmbH

**Bronze Circle Corporate Members:**
MSD Sharp & Dohme GmbH (Meet-the-Professor Session)
Novartis Pharma GmbH (Meet-the-Professor Session)

**Other Corporate Support:**
Abbott GmbH & Co. KG
Bayer Vital GmbH
Celgene GmbH
Genzyme GmbH
Helmholtz Zentrum Munich
Medac GmbH (Poster Awards)

**Companies Participating in the Commercial Exhibition (preliminary list):**
Amgen GmbH
Cephalon Pharma GmbH
GILEAD Sciences GmbH
GlaxoSmithKline
Hoffmann-La Roche AG
Janssen-Cilag GmbH
MEDA Pharma GmbH & Co. KG
MSD Sharp & Dohme GmbH
Mundipharma GmbH
Novartis Pharma GmbH
Pfizer Pharma GmbH
Ratiopharm direct GmbH
Satellite Symposium I

Follicular Lymphoma – Maintenance Therapy and Beyond

(sponsored by Hoffmann-La-Roche Pharma AG)

Chairman:
M. Dreyling, Munich, G

G. Salles, Lyon, F
First Line Therapy – The PRIMA Study Results

T. Hagenbeek, Utrecht, NL
Second Line Therapy – The EORTC Study Data

W. Hiddemann, Munich, G
Future Strategies – GA 101

DISCUSSION
Satellite Symposium II

Current Status of Therapy in Indolent Lymphomas in Germany

(sponsored by mundipharma GmbH)

Chairman:
M. Herold, Erfurt, G

M. Rummel, Gießen, G
STIL Results

W. Hiddemann, Munich, G
GLSG Results

DISCUSSION
13.00-14.45 (HS III)  Satellite Symposium III

*Postremission Treatment of Acute Myeloid Leukemia*

(sponsored by MEDA Pharma GmbH & Co. KG)

**Chairman:**
Th. Büchner, Münster, G

**Th. Büchner, Münster, G**
*Overview of Postremission Treatment Approaches*

**J. Rowe, Haifa, IL**
*Maintenance Therapy of AML*

**K. Hellstrand, Goteborg, S (tbc)**
*Postconsolidation Immunotherapy with Histamine Dihydrochloride and Interleukin 2 in Acute Myeloid Leukemia*

**DISCUSSION**
### Satellite Symposium IV

**Invasive Fungal Disease: Lung Infiltrates as „Surrogat“ marker for IFD?**

*(sponsored by GILEAD Sciences GmbH)*

**Chairman:**
H. Einsele, Würzburg, G

**R. Bialek, Kiel, G**
*C*an *Microbiology Establish the Causative Agents?*

**H. Ostermann, Munich, G**
*What Are the Economical Consequences of Lung Infiltrates?*

---

**DISCUSSION**
**Symposium Arbeitsgemeinschaft Infektionen in der Hämatologie und Onkologie**

*Invasive Fungal Infections in 2011 – Diagnosis and Treatment*

**Chairpersons:**
G. Maschmeyer, Potsdam, G  
H. Ostermann, Munich, G

**C. Lass-Flörl, Innsbruck, A**  
*Epidemiology and Resistance of Fungi: Is the Enemy Changing his Face?*

**C.P. Heussel, Heidelberg, G**  
*The Irregular Infiltrate: Do we Know what we See on CT Scans?*

**O. Cornely, Cologne, G**  
*Prophylaxis in AML Induction: yes; Consolidation: no?*

**G. Maschmeyer, Potsdam, G**  
*Is it Time to Switch from Empirical to Preemptive Treatment of IFI?*

**H. Ostermann, Munich, G**  
*Cerebral Fungal Infections: How to Diagnose and Treat*
MONDAY, Feb 28, 2011

09.00-09.30  Welcome Addresses

M. Reiser, Munich
Dean Faculty of Medicine

G. Ehninger, Dresden
President German Society for Hematology and Oncology

G. Wess, Munich
Chairman HelmholtzZentrum München
German Research Center for Environment and Health

W. Hiddemann, Munich
Symposium Chairman

09.30-10.15  Special Lecture

Chairman:
W. Hiddemann, Munich

Introduction:
D. Hoelzer, Frankfurt, G

M. Greaves, Aberdeen, UK
Genetic Architecture of Leukaemia

10.15-10.45  Coffee Break
M O N D A Y , Feb 28, 2011

10.45-12.25  
Main Session I
Characterization of Leukemic Stem Cells

Chairmen:
W.E. Fibbe, Leiden, NL
T. Schroeder, Neuherberg, G

11.05-11.25  
C. Eaves, Vancouver, Can
WWW.Malignant Stem Cells – What, When, Why

11.25-11.45  
C. Buske, Munich, G
Promiscuity of Leukemic Stem Cells

11.45-12.05  
T. Lapidot, Rehovot, ISR
Regulation of Normal and Leukemic Human Stem Cells via Dynamic Interactions of the Nervous and Immune Systems with the Microenvironment

12.05-12.25  
B. Huntly, Cambridge, UK
Common Programs in Leukemic Stem Cells

12.25 – 14.00  Lunch Break

12.45-13.45 (HS II)  
Meet-the-Professor Session

Chairperson: J. Braess, Munich, G

A. Hochhaus, Jena, G
Myeloproliferative Neoplasia – New Concepts in the Treatment of Chronic Myeloid Leukemia

(sponsored by Novartis Pharma GmbH)
MONDAY, Feb 28, 2011

14.00 – 15.40  Main Session II
Genetic and Molecular Characterization of Acute Leukemias

Chairmen:
S. Amadori, Rome, I
J. Duyster, Munich, G

14.00-14.20  H. Döhner, Ulm, G
Biologic and Clinical Risk Groups in AML

14.20-14.40  B.A. Falini, Perugia, I
Biology of NPM+ AML

14.40-15.00  J. Licht, Chicago, USA (tbc)
Biology of PML/RARA Positive AML

15.00-15.20  St. K. Bohlander, Munich, G
Characterization of CALM/AF 10 Leukemias

15.20-15.40  T. Graubert, St. Louis, USA
Characterization of AML by Whole Genome Sequencing

15.40 – 16.10  Coffee Break

ACUTE LEUKEMIAS XIII
Biology and Treatment Strategies
16.10 – 18.00  Main Session III  
Biology and Management of AML with t(15;17)  

Chairmen: 
W.-K. Hofmann, Mannheim, G  
R. Hills, Cardiff, UK  

16.10-16.30  M. Sanz, Valencia, E  
The PETHEMA Data  

16.30-16.50  E. Lengfelder, Mannheim, G  
The AMLCG Results  

16.50-17.10  F. Lo Coco, Rome, I  
The GIMEMA Data  

17.10-17.20  P. Fenaux, Bobigny, F  
The French Belgian Swiss APL Group Data  

17.20-17.40  M.S. Tallman, Chicago, USA  
Curing APL without (much) Chemotherapy  

17.40-18.00  D. J. Grimwade, London, UK  
MRD directed Therapy of APL  

18.00 – 19.30  Main Session IV  
Poster Viewing and Discussion
T U E S D A Y , Mar 1 , 2011

09.00 – 10.40  Main Session V
Risk Adapted Therapy of AML

Chairmen:
Ch.A. Schiffer, Detroit, USA
W.E. Berdel, Münster, G

09.00-09.20  U. Creutzig, Münster, G
Results of Study AML-BFM 2004 Support the Need for further Risk-adapted Treatment Options

09.20-09.40  J. Braess, Munich, G
Dose Dense Induction – AMLCG Results

09.40-10.00  R.M. Stone, Boston, USA
FLT 3 Inhibition – Update

10.00-10.20  H. Serve, Frankfurt, G
FLT 3 Inhibition in AML – SAL Data

10.20-10.40  A.K. Burnett, Cardiff, UK
The MRC Data on Gemtuzumab

10.40 – 11.10  Coffee Break
TUESDAY, Mar 1, 2011

11.10 – 13.10  Main Session VI
Management of Elderly and Frail Patients with AML

Chairmen:
J.M. Rowe, Haifa, IL
B. Wörmann, Bremen, G

11.10-11.30  C.D. Bloomfield, Columbus, USA
Molecular Markers in Elderly AML

11.30-11.50  E.H. Estey, Seattle, USA
Selection of Intensive Treatment for Elderly Patients with AML

11.50-12.10  Th. Büchner, Münster G
AMLCG Results in Elderly AML

12.10-12.30  A.K. Burnett, Cardiff, UK
MRC Results in Elderly AML

12.30-12.50  K. Spiekermann, Munich G
Selection and Non-Intensive Therapy of Frail Patients with AML

12.50-13.10  C. Gardin, Bobigny, F
Azacytidine Therapy for Elderly Patients with AML

13.10 – 14.15  Lunch Break

13.30-14.00  Meet-the-Professor Session (HS II)

H. Ostermann, Munich, G
Treatment Strategies in Invasive Mycoses: Pre-emptive vs. Empiric

(sponsored by MSD Sharp & Dohme GmbH)
Main Session VII
Relevance of Minimal Residual Disease in AML and ALL

Chairmen:
M.-C. Béné, Nancy, F
R. Hehlmann, Mannheim, G

14.15-14.35
J.M. van Dongen, Rotterdam, NL
Innovation and International Standardization of MRD Monitoring

14.35-14.55
M. Kneba, Kiel, G
MRD directed Therapy of Adult ALL

14.55-15.15
A. Biondi, Monza, I
MRD directed Therapy of Childhood ALL

15.15-15.35
K. Döhner, Ulm, G
Monitoring of NPM 1 Mutations in AML Therapy

15.35-15.55
J.P. Radich, Seattle, USA
Flow Cytometry versus Molecular Analyses for MRD Monitoring

15.55 – 16.25
Coffee Break
Tuesday, Mar 1, 2011

16.25 – 18.05 Main Session VIII
Immunotherapy of Acute Leukemias

Chairmen:
D. Schendel, Munich, G
M. Manz, Zurich, CH

16.25-16.45 H. Schreiber, Chicago, USA
Principles of Immunotherapy in Acute Leukemias

16.45-17.05 P. Greenberg, Seattle, USA
TCR directed Immunotherapy of AML

17.05-17.25 M. Subklewe, Munich, G
Vaccination with Dendritic Cells in AML

17.25-17.45 M. Schmitt, Rostock, G
Peptide Vaccination in AML

17.45-18.05 N. Gögkbuget, Frankfurt, G
Immunotherapy with Bi-Specific Antibodies in ALL

18.05-18.30 Coffee Break

18.30-19.15 Main Session IX
Best of Free Contributions
ACUTE LEUKEMIAS XIII
Biology and Treatment Strategies

W E D N E S D A Y , Mar 2, 2011

09.00 – 10.40  Main Session X
Risk Adapted Therapy of ALL

Chairmen:
O.G. Ottmann, Frankfurt, G
R. Foa, Rome, I

09.00-19.20  J. Downing, Memphis, USA
Molecular Pathogenesis of Acute Leukemia

09.20-09.40  H.C. Pui, Memphis, USA
Treatment of Childhood ALL without Cranial Irradiation

09.40-10.00  M. Schrappe, Kiel, G
Results of the BFM/AIEOP Studies

10.00-10.20  D. Hoelzer, N. Gögkbuget, Frankfurt, G
Treatment Results in B-ALL

10.20-10.40  R.A. Larson, Chicago, USA
Therapy of Ph+ ALL

10.40 – 11.10  Coffee Break
WEDNESDAY, Mar 2, 2011

11.10 – 12.50 Main Session XI
Allogeneic Transplantation

Chairmen:
A.H. Goldstone, London, UK (tbc)
D.W. Beelen, Essen, G

11.10-11.30 M.F. Martelli, Perugia, I
Adoptive Immunotherapy with Donor T regs in
HLA Haploidentical Transplantation

11.30-11.50 J.E. Wagner, Minneapolis, USA
Cord Blood Transplantation

11.50-12.10 D. Niederwieser, Leipzig, G
Transplantation as integral Part of Treatment in Elderly
Patients with AML

12.10-12.30 J. Kienast, Münster, G
Dose Reduced versus Conventional Conditioning

12.30-12.50 C. Schmid, Augsburg, G
Sequential Therapy for High Risk AML

12.50 – 13.00 Closing Remarks
Th. Büchner, Münster, G
Symposium Chairman
### Price range

<table>
<thead>
<tr>
<th>Single Room</th>
<th>Double Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>A ab / over</td>
<td>A ab / over</td>
</tr>
<tr>
<td>150,- €</td>
<td>200,- €</td>
</tr>
<tr>
<td>B von / from</td>
<td>B von / from</td>
</tr>
<tr>
<td>90,- €</td>
<td>140,- €</td>
</tr>
<tr>
<td>bis / to</td>
<td>bis / to</td>
</tr>
<tr>
<td>150,- €</td>
<td>200,- €</td>
</tr>
<tr>
<td>C von / from</td>
<td>C von / from</td>
</tr>
<tr>
<td>60,- €</td>
<td>90,- €</td>
</tr>
<tr>
<td>bis / to</td>
<td>bis / to</td>
</tr>
<tr>
<td>90,- €</td>
<td>140,- €</td>
</tr>
<tr>
<td>D von / from</td>
<td>D von / from</td>
</tr>
<tr>
<td>40,- €</td>
<td>50,- €</td>
</tr>
<tr>
<td>bis / to</td>
<td>bis / to</td>
</tr>
<tr>
<td>60,- €</td>
<td>90,- €</td>
</tr>
</tbody>
</table>

Categories A, B and C: with bath or shower and WC/C.

Category D: mostly with shower and WC down the hall.

The rates are per room and night, including breakfast, service and taxes.

Please reserve obligatory for the period stated below:

- Ankunft am / arrival on ________ um / at _______ h.
- Abreise am / departure on ________

<table>
<thead>
<tr>
<th>price range</th>
<th>A □</th>
<th>B □</th>
<th>C □</th>
<th>D □</th>
<th>please mark</th>
</tr>
</thead>
</table>

If the desired price range is no longer available, I also agree to the group ________________________________

Besondere Wünsche / special wishes ____________________________________________________________

(please fold here)

Name of Person requesting room:

__________________________________________ ____________
Name / name Vorname / first name Straße / street Hausnummer / No.

__________________________________________ ____________
Firma / office Postleitzahl / zip code Ort / town

__________________________________________
Telefon Fax E-Mail

Kreditkarte / Creditcard □ Visa □ Eurocard/Mastercard □ American Express □ Diners Club

Kreditkartenummer / Card Number________________________ Gültig bis / valid until ____________

I have duly noted the conditions for the reservation (see below).

__________________________________________ ____________
City Date Signature
Dear Visitor(s), please note:

Room reservations are handled in the order they are received. For this reason it is advisable to order rooms as soon as possible. With this booking confirmation by the Munich Tourist Office you have become immediate contractual partner with the hotel booked and on the conditions of the German Hotel Reservations Contract settled by DEHOGA. The Munich Tourist Office is only the mediator of this room reservation and does not assume any liability for the service and efficiency offered by the hotel.

Rights and Obligations of the Hotel Reservations Contract

1. The contract between guest and hotel enterprise is considered concluded as soon as the room has been reserved and the reservation confirmed, or in the event that there is no time for confirmation – as soon as the room has been reserved.

2. The contract when concluded obliges both contractual partners to fulfilment of all contract conditions, regardless of the length of time for which the contract has been concluded.

3. The hotelier is obligated, in case the booked room is not available, to make good the damages to the guest.

4. The guest is obligated, by non-occupancy of the room or by non use of other contract benefits, to pay the agreed price for such, or the normal hotel price, minus any savings of expense made by the hotelier.

Absender / Sender

___________________________________________
Name / name Vorname / first name

___________________________________________
Hospital / Institute / Company

___________________________________________
Department

___________________________________________
Straße / Street Nr. / no.

___________________________________________
Postleitzahl / zip code Ort / town / country

Since space is limited please mail until Jan 16, 2011 to:

Landeshauptstadt München
Referat für Arbeit und Wirtschaft
Tourismusamt
Sendlinger Straße 1
D-80331 München
Germany
ORGANIZING COMMITTEE:

Prof. Dr. W. Hiddemann, Munich  
Prof. Dr. Th. Büchner, Münster  
Prof. Dr. J. Braess, Munich  
Priv.-Doz. Dr. K. Spiekermann, Munich  
Priv.-Doz. Dr. M. Subklewe, Munich  
Dr. O. Christ, Munich

ORGANIZING OFFICE:

Beate Buske-Kosel, M.A.  
Am Webstuhl 5  
D-59227 Ahlen  
Germany  
Phone: +49-(0)2382-7601 457 (new number valid after Nov 8, 2010)  
Fax:     +49-(0)2382-7601 458 (new number valid after Nov 8, 2010)  
e-mail: info@acute-leukemias.de

Aleksandra Schydlik  
Department of Internal Medicine III  
University Hospital Großhadern  
Ludwig-Maximilians-University  
Marchioninstraße 15  
D-81377 Munich, Germany  
Phone:  +49(0)89-7095 5530  
Fax:      +49(0)89-7095 5550

OFFICIAL HOMEPAGE  
FOR ELECTRONIC REGISTRATION:

www.acute-leukemias.de